Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C26H17ClF9N3O3 |
| Molecular Weight | 625.87 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)(F)CNC(=O)CNC(=O)C1=C2C=CC=CC2=C(C=C1)C3=NOC(C3)(C4=CC(=CC(Cl)=C4)C(F)(F)F)C(F)(F)F
InChI
InChIKey=OXDDDHGGRFRLEE-UHFFFAOYSA-N
InChI=1S/C26H17ClF9N3O3/c27-15-8-13(7-14(9-15)25(31,32)33)23(26(34,35)36)10-20(39-42-23)18-5-6-19(17-4-2-1-3-16(17)18)22(41)37-11-21(40)38-12-24(28,29)30/h1-9H,10-12H2,(H,37,41)(H,38,40)
| Molecular Formula | C26H17ClF9N3O3 |
| Molecular Weight | 625.87 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Afoxolaner (brand name NexGard) is a member of an isoxazoline class of compounds, which is used to kill adult fleas and is indicated for the treatment and prevention of flea infestations, and the treatment and control of Black-legged tick, American Dog tick, Lone Star tick, and Brown dog tick infestations in dogs and puppies. Afoxolaner is a member of the isoxazoline family, shown to bind at a binding site to inhibit insect and acarine ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA), thereby blocking pre- and post-synaptic transfer of chloride ions across cell membranes. Afoxolaner blocks native and expressed insect GABA-gated chloride channels with nanomolar potency. Prolonged afoxolaner-induced hyperexcitation results in uncontrolled activity of the central nervous system and death of insects and acarines.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: insect and acarine GABA-gated chloride channels Sources: https://www.ncbi.nlm.nih.gov/pubmed/24631502 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | NEXGARD Approved UseUnknown |
|||
| Curative | NEXGARD Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Evaluation of the efficacy of monthly oral administration of afoxolaner plus milbemycin oxime (NexGard Spectra(®), Merial) in the prevention of adult Spirocerca lupi establishment in experimentally infected dogs. | 2016-08-15 |
|
| Discovery and mode of action of afoxolaner, a new isoxazoline parasiticide for dogs. | 2014-04-02 |
|
| Evaluation of the efficacy of afoxolaner against Haemaphysalis longicornis on dogs. | 2014-04-02 |
|
| Afoxolaner against fleas: immediate efficacy and resultant mortality after short exposure on dogs. | 2014 |
Sample Use Guides
in veterinary:
NexGard is given orally once a month, at the minimum dosage of 1.14 mg/lb (2.5 mg/kg).
Dosing Schedule:
Body Weight Afoxolaner Per Chewable (mg) Chewables Administered
4.0 to 10.0 lbs. 11.3 One
10.1 to 24.0 lbs. 28.3 One
24.1 to 60.0 lbs. 68 One
60.1 to 121.0 lbs. 136 One
Over 121.0 lbs. Administer the appropriate combination of chewables
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24631502
A dosage and time titration effect was clearly identified for fleas ingesting afoxolaner with mean efficacies of >95% recorded for fleas fed blood containing the compound at concentrations of 0.16, 0.08 and 0.02 μg/ml at the 24, 48 and 72 h observation points, respectively. There was only 1%, 2.3% and 2.3% mean mortality in the vehicle-treated control at the 24, 48 and 72 h observation points, respectively. Therefore, afoxolaner was judged to be highly active against fleas following ingestion in blood.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:41:31 GMT 2025
by
admin
on
Mon Mar 31 21:41:31 GMT 2025
|
| Record UNII |
02L07H6D0U
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EMA VETERINARY ASSESSMENT REPORTS |
NEXGARD SPECTRA [AUTHORIZED]
Created by
admin on Mon Mar 31 21:41:31 GMT 2025 , Edited by admin on Mon Mar 31 21:41:31 GMT 2025
|
||
|
CFR |
21 CFR 520.43
Created by
admin on Mon Mar 31 21:41:31 GMT 2025 , Edited by admin on Mon Mar 31 21:41:31 GMT 2025
|
||
|
WHO-VATC |
QP53BX04
Created by
admin on Mon Mar 31 21:41:31 GMT 2025 , Edited by admin on Mon Mar 31 21:41:31 GMT 2025
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
NEXGARD [AUTHORIZED]
Created by
admin on Mon Mar 31 21:41:31 GMT 2025 , Edited by admin on Mon Mar 31 21:41:31 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C171791
Created by
admin on Mon Mar 31 21:41:31 GMT 2025 , Edited by admin on Mon Mar 31 21:41:31 GMT 2025
|
PRIMARY | |||
|
1093861-60-9
Created by
admin on Mon Mar 31 21:41:31 GMT 2025 , Edited by admin on Mon Mar 31 21:41:31 GMT 2025
|
PRIMARY | |||
|
ZZ-56
Created by
admin on Mon Mar 31 21:41:31 GMT 2025 , Edited by admin on Mon Mar 31 21:41:31 GMT 2025
|
PRIMARY | |||
|
m11748
Created by
admin on Mon Mar 31 21:41:31 GMT 2025 , Edited by admin on Mon Mar 31 21:41:31 GMT 2025
|
PRIMARY | |||
|
afoxolaner
Created by
admin on Mon Mar 31 21:41:31 GMT 2025 , Edited by admin on Mon Mar 31 21:41:31 GMT 2025
|
PRIMARY | |||
|
300000023671
Created by
admin on Mon Mar 31 21:41:31 GMT 2025 , Edited by admin on Mon Mar 31 21:41:31 GMT 2025
|
PRIMARY | |||
|
DTXSID50148921
Created by
admin on Mon Mar 31 21:41:31 GMT 2025 , Edited by admin on Mon Mar 31 21:41:31 GMT 2025
|
PRIMARY | |||
|
Afoxolaner
Created by
admin on Mon Mar 31 21:41:31 GMT 2025 , Edited by admin on Mon Mar 31 21:41:31 GMT 2025
|
PRIMARY | |||
|
CHEMBL2219412
Created by
admin on Mon Mar 31 21:41:31 GMT 2025 , Edited by admin on Mon Mar 31 21:41:31 GMT 2025
|
PRIMARY | |||
|
02L07H6D0U
Created by
admin on Mon Mar 31 21:41:31 GMT 2025 , Edited by admin on Mon Mar 31 21:41:31 GMT 2025
|
PRIMARY | |||
|
9697
Created by
admin on Mon Mar 31 21:41:31 GMT 2025 , Edited by admin on Mon Mar 31 21:41:31 GMT 2025
|
PRIMARY | |||
|
25154249
Created by
admin on Mon Mar 31 21:41:31 GMT 2025 , Edited by admin on Mon Mar 31 21:41:31 GMT 2025
|
PRIMARY | |||
|
02L07H6D0U
Created by
admin on Mon Mar 31 21:41:31 GMT 2025 , Edited by admin on Mon Mar 31 21:41:31 GMT 2025
|
PRIMARY | |||
|
1442093
Created by
admin on Mon Mar 31 21:41:31 GMT 2025 , Edited by admin on Mon Mar 31 21:41:31 GMT 2025
|
PRIMARY | RxNorm |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |